Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Kety Huberman"'
Autor:
Dana W. Y. Tsui, Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis Stephens, Helen Won, Preethi Srinivasan, Kety Huberman, Fanli Meng, Xiaohong Jing, Juber Patel, Maysun Hasan, Ian Johnson, Erika Gedvilaite, Brian Houck-Loomis, Nicholas D. Socci, S. Duygu Selcuklu, Venkatraman E. Seshan, Hongxin Zhang, Debyani Chakravarty, Ahmet Zehir, Ryma Benayed, Maria Arcila, Marc Ladanyi, Samuel A. Funt, Darren R. Feldman, Bob T. Li, Pedram Razavi, Jonathan Rosenberg, Dean Bajorin, Gopa Iyer, Wassim Abida, Howard I. Scher, Dana Rathkopf, Agnes Viale, Michael F. Berger, David B. Solit
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-15 (2021)
Abstract Background Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulatin
Externí odkaz:
https://doaj.org/article/a175329a098b4151983ca7a727781ce0
Autor:
Prachi Kothari, Francesco Marass, Julie L. Yang, Caitlin M. Stewart, Dennis Stephens, Juber Patel, Maysun Hasan, Xiaohong Jing, Fanli Meng, Jeanette Enriquez, Kety Huberman, Agnes Viale, Jasmine H. Francis, Michael F. Berger, Neerav Shukla, David H. Abramson, Ira J. Dunkel, Dana W.Y. Tsui
Publikováno v:
Cancer Medicine, Vol 9, Iss 17, Pp 6093-6101 (2020)
Abstract Purpose The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinob
Externí odkaz:
https://doaj.org/article/0a8e616f72034103b531f13b624076ea
Autor:
Justin Rendleman, Yevgeniy Antipin, Boris Reva, Christina Adaniel, Jennifer A Przybylo, Ana Dutra-Clarke, Nichole Hansen, Adriana Heguy, Kety Huberman, Laetitia Borsu, Ora Paltiel, Dina Ben-Yehuda, Jennifer R Brown, Arnold S Freedman, Chris Sander, Andrew Zelenetz, Robert J Klein, Yongzhao Shao, Mortimer Lacher, Joseph Vijai, Kenneth Offit, Tomas Kirchhoff
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101685 (2014)
Molecular and genetic evidence suggests that DNA repair pathways may contribute to lymphoma susceptibility. Several studies have examined the association of DNA repair genes with lymphoma risk, but the findings from these reports have been inconsiste
Externí odkaz:
https://doaj.org/article/3f64b33497e7444c8525efdd3f910822
Autor:
Kelly Coffey, Timothy J Blackburn, Susan Cook, Bernard T Golding, Roger J Griffin, Ian R Hardcastle, Lorraine Hewitt, Kety Huberman, Hesta V McNeill, David R Newell, Celine Roche, Claudia A Ryan-Munden, Anna Watson, Craig N Robson
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e45539 (2012)
Tip60 (KAT5) is a histone acetyltransferase (HAT enzyme) involved in multiple cellular processes including transcriptional regulation, DNA damage repair and cell signalling. In prostate cancer, aggressive cases over-express Tip60 which functions as a
Externí odkaz:
https://doaj.org/article/ad0f8a29724847c78bbacae4be080277
Autor:
Lee M. Krug, Mark G. Kris, Gregory J. Riely, Christopher G. Azzoli, Naiyer A. Rizvi, Timothy A. Chan, Andrei I. Holodny, Michelle S. Ginsberg, Adriana Heguy, William D. Travis, Dyana K. Sumner, John J. Fiore, Camelia S. Sima, Kety Huberman, Kyuichi Kadota, M. Catherine Pietanza
PDF file - 39K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3040e360d2af948eb11e1725328e81
https://doi.org/10.1158/1078-0432.22443855
https://doi.org/10.1158/1078-0432.22443855
Autor:
Lee M. Krug, Mark G. Kris, Gregory J. Riely, Christopher G. Azzoli, Naiyer A. Rizvi, Timothy A. Chan, Andrei I. Holodny, Michelle S. Ginsberg, Adriana Heguy, William D. Travis, Dyana K. Sumner, John J. Fiore, Camelia S. Sima, Kety Huberman, Kyuichi Kadota, M. Catherine Pietanza
PDF file - 55K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5169fcc4ed19230bb7c0a5915a7e797e
https://doi.org/10.1158/1078-0432.22443852
https://doi.org/10.1158/1078-0432.22443852
Autor:
Lee M. Krug, Mark G. Kris, Gregory J. Riely, Christopher G. Azzoli, Naiyer A. Rizvi, Timothy A. Chan, Andrei I. Holodny, Michelle S. Ginsberg, Adriana Heguy, William D. Travis, Dyana K. Sumner, John J. Fiore, Camelia S. Sima, Kety Huberman, Kyuichi Kadota, M. Catherine Pietanza
Purpose: This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC).Experimental Design: Patients with disease progression after one or two prior chemotherapy regimens received tem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86885f64f64e161fcb99cc8353bcb9f
https://doi.org/10.1158/1078-0432.c.6519984
https://doi.org/10.1158/1078-0432.c.6519984
Autor:
David B. Solit, Philip B. Paty, Adriana Heguy, Leonard B. Saltz, Marc Ladanyi, Alex Lash, John M. Mariadason, Suresh C. Jhanwar, James A. Fagin, Douglas A. Levine, Yogindra Persaud, Julio Cezar Ricarte Filho, Kety Huberman, Manda Wilson, Ensar Halilovic, Dhananjay Chitale, Barry S. Taylor, Christine A. Pratilas, Zhaoshi Zeng, Efsevia Vakiani, Manickam Janakiraman
Supplementary Figures 1-3, Tables 1-9, Methods from Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62ed49f3f3781aad5e9033366ee6c4f
https://doi.org/10.1158/0008-5472.22383576.v1
https://doi.org/10.1158/0008-5472.22383576.v1
Autor:
David B. Solit, Philip B. Paty, Adriana Heguy, Leonard B. Saltz, Marc Ladanyi, Alex Lash, John M. Mariadason, Suresh C. Jhanwar, James A. Fagin, Douglas A. Levine, Yogindra Persaud, Julio Cezar Ricarte Filho, Kety Huberman, Manda Wilson, Ensar Halilovic, Dhananjay Chitale, Barry S. Taylor, Christine A. Pratilas, Zhaoshi Zeng, Efsevia Vakiani, Manickam Janakiraman
Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor (EGFR)–targeted therapies, limited clinical testing for RAS pathway muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4155bfa59f0aaa6b4ba6253d78cf53a
https://doi.org/10.1158/0008-5472.c.6500589
https://doi.org/10.1158/0008-5472.c.6500589
Autor:
Ritesh R. Kotecha, Erika Gedvilaite, Ryan Ptashkin, Andrea Knezevic, Samuel Murray, Ian Johnson, Natalie Shapnik, Darren R. Feldman, Maria I. Carlo, Neil J. Shah, Marisa Dunigan, Kety Huberman, Ryma Benayed, Ahmet Zehir, Michael F. Berger, Marc Ladanyi, Dana W. Y. Tsui, Robert J. Motzer, Chung-Han Lee, Martin H. Voss
Publikováno v:
JCO Precis Oncol
PURPOSE The clinical utility of cell-free DNA (cfDNA) as a biomarker for advanced clear cell renal cell carcinoma (ccRCC) remains unclear. We evaluated the validity of cfDNA-based genomic profiling in a large cohort of patients with ccRCC with matche